Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabol-MG adjunctive therapy in type 2 diabetes with hypomagnesemia
2009-014350-15Phase 2Terminated
- Sponsor
- Tecnimede
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mono-magnesium L-aspartate hydrochloride in type 2 diabetes mellitus (T2DM) and hypomagnesaemia (2 arms), sponsored by Tecnimede. Primary endpoint: Change in HbA1c from baseline to day 120. Started Mar 2010; status: terminated.
02
Drugs
mono-magnesium L-aspartate hydrochloride
03
Conditions
type 2 diabetes mellitus (T2DM)hypomagnesaemia
Beyond the preview
Go deeper on 2009-014350-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014350-15.